Novel de novo POLR3B mutations responsible for demyelinating Charcot-Marie-Tooth disease in Japan

Masahiro Ando1, Yujiro Higuchi1, Jun-Hui Yuan1

  • 1Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

Abstract

Insights

Genetic analysis identified de novo POLR3B mutations in two patients with early-onset demyelinating Charcot-Marie-Tooth disease. This confirms POLR3B mutations as a cause of demyelinating neuropathy and warrants inclusion in genetic screening panels.

Area of Science:

  • Genetics
  • Neurology
  • Molecular Biology

Background:

  • Biallelic POLR3B mutations cause hypomyelinating leukodystrophy.
  • De novo POLR3B mutations are linked to ataxia, spasticity, intellectual disability, epilepsy, and demyelinating neuropathy.

Purpose of the Study:

  • To investigate POLR3B mutations in Charcot-Marie-Tooth (CMT) cases.
  • To confirm the clinical features associated with POLR3B mutations in CMT.

Main Methods:

  • Whole-exome sequencing (WES) of 804 undiagnosed CMT cases.
  • Analysis of POLR3B mutations and their clinical correlations.

Main Results:

  • Identified de novo POLR3B heterozygous missense mutations in two patients with early-onset demyelinating sensorimotor neuropathy.
  • Patients lacked ataxia, spasticity, and cognitive impairment; one experienced respiratory failure.
  • Mutations were classified as pathogenic through segregation studies, database comparison, and in silico analysis.

Conclusions:

  • This study verifies the pathogenicity of POLR3B mutations in demyelinating CMT.
  • POLR3B mutations should be included in genetic screening panels for early-onset demyelinating CMT.